CoChat

Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada

Tunis, Sandra L., Sauriol, Luc, Minshall, Michael E. · 2010 · Applied Health Economics and Health Policy

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background Several treatment options are available for patients with type 2 diabetes mellitus who are making the transition from oral antidiabetes drugs (OADs) to insulin. Two options currently recommended by the Canadian Diabetes Association for initiating insulin therapy in patients with type 2 diabetes who are no longer responsive to OADs alone are insulin glargine plus OADs, and premixed insulin therapy only. Because of differences in efficacy, adverse events (such as hypoglycaemia) and acquisition costs, these two treatment options may lead to different long-term clinical and economic outcomes. Objective To determine the cost effectiveness of insulin glargine plus OADs compared with premixed insulin without OADs in insulin-naive patients with type 2 diabetes in Canada. Methods Using treatment effects taken from a published clinical trial, the validated IMS-CORE Diabetes Model was used to simulate the long-term cost effectiveness of insulin glargine with OADs, versus premixed insulin. Input treatment effects for the two therapeutic approaches were based on changes in glycosylated haemoglobin A(1c) (HbA(1c)) at clinical trial endpoint, and hypoglycaemia rates. The analysis was conducted from the perspective of the Canadian Provincial payer. Direct treatment and complication costs were obtained from published sources (primarily from Ontario) and reported in $Can, year 2008 values. All base-case costs and outcomes were discounted at 5% per year. Sensitivity analyses were con…

Overview

Integrity signals

Registry

Crossref · 10.2165/11535380-000000000-00000

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 3

  1. 2008, Can J Diabetes, 32, 1
  2. Moss, 1992, Arch Inter Med, 152, 610, 10.1001/archinte.1992.00400150120022 · doi:10.1001/archinte.1992.00400150120022 · Paper page
  3. Currie, 2005, Diabetologia, 48, A292

Cited by

See all 22

Metadata

Authors
Tunis, S. L., Sauriol, L., & Minshall, M. E.
Affiliations
  • IQVIA (United States) (US)
  • Sanofi (Canada) (CA)
Corresponding author
Sauriol, Luc
Venue
Applied Health Economics and Health Policy
Published
2010-07
Volume
8
Issue
4
Pages
267-280
ISSN
1175-5652 (ISSN-L)
OpenAlex
W1994423404
Cited by
21
References
26
Citations by year
2022: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 2 · 2013: 2 · 2012: 2
FWCI
1.21
Type
journal article
Language
en
Open access
closed
Locations
  • Applied Health Economics and Health Policy (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Sanofi
  • Public Health Agency of Canada
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin glargine, oral antidiabetic drugs, premixed insulin, type 2 diabetes, cost-effectiveness, insulin initiation, hypoglycemia, glycemic control, diabetes complications, quality-adjusted life years, incremental cost-effectiveness ratio, Ontario, willingness to pay
MeSH terms
Insulin Glargine, Canada, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Quality-Adjusted Life Years, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. https://app.cochat.ai/papers/10.2165/11535380-000000000-00000
The paper
Tunis, S. L., Sauriol, L., & Minshall, M. E. (2010). Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. Applied Health Economics and Health Policy. https://doi.org/10.2165/11535380-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.